Cell & Gene Therapy Sector – Influential Manufacturing Developments & Pertinent Competitive Dynamics

  • Public Equity
  • Healthcare
  • North America


Former senior director at Thermo Fisher Scientific Inc


  • Major developments within the C&GT (cell and gene therapy) space, highlighting ongoing manufacturing advancements for CDMOs (contract development and manufacturing organisations)
  • Progression of newer modalities, including GMP (good manufacturing practice)-related products, dosing to modules, viral vs non-viral and addressing the autologous vs analogous question
  • Comparative dynamics among operating C&GT players such as Thermo Fisher (NYSE: TMO), Resilience, Danaher’s Cytiva (NYSE: DHR), Lonza (VTX: VONN), Miltenyi Biotec and Catalent (NYSE: CTLT)
  • Technical challenges and expertise required to manoeuvre C&GT products, breaking down automation and flexibility efforts
  • 12-18-month outlook for the C&GT manufacturing industry, discussing future scalability and standardisation options


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited